Contribution of concomitant myocarditis to the development of various clinical types of arrhythmogenic right ventricular cardiomyopathy

Aim. To assess the contribution of genetic and inflammatory factors to the development of arrhythmogenic right ventricular cardiomyopathy (ARVC).

Material and methods. The study involved 54 patients with ARVC (age, 38,7±14,1 years; men, 42,6%; mean follow-up period, 21 [6; 60] months). All patients underwent electrocardiography (ECG), 24-hour ECG monitoring, echocardiography, determination of anticardiac antibodies and DNA of cardiotropic viruses in the blood, molecular genetic ARVC testing, as well as cardiac magnetic resonance imaging (n=49), high-resolution ECG (n=18), right ventricular endomyocardial biopsy (n=2), and autopsy (n=2).

Results. Following four clinical types of ARVC were identified: I. Latent arrhythmic form: characterized by frequent premature ventricular contractions and/or nonsustained ventricular tachycardia (VT). II. Manifested arrhythmic form (n=11) — SVT/ventricular fibrillation (VF). III. ARVC with progressive heart failure (HF, n=8). IV. Combination of ARVC with left ventricular noncompaction (LVNC, n=8). Superimposed myocarditis was identified in 74%, 36%, 87,5% and 85,7% of patients in forms I-IV, respectively. Mutations were detected in 11%, 46%, 50%, and 38% of patients in forms I-IV, respectively. Clinical forms were stable: there was no transition from one clinical form to another during follow-up period.

Conclusion. The contribution of genetic and inflammatory mechanisms to the clinical picture is different: in the latent arrhythmic form, the leading role belongs to inflammation; in the manifested arrhythmic form, the contribution of pathogenic mutations prevails, and in ARVC with progressive HF and in combination with LVNC, the contribution of genetic and inflammatory factors is equally important.

1. Corrado D, Wichter T, Link MS, et al. Treatment of arrhythmogenic right ventricular cardiomyopathy/dysplasia: an international task force consensus statement. Eur Heart J. 2015;36:3227-37. doi:10.1093/eurheartj/ehv162.

2. Fontaine G, Fontaliran F, Frank R. Arrhythmogenic Right Ventricular Cardiomyopathies: Clinical Forms and Main Differential Diagnoses. Circulation. 1998;97:1532-5. doi:10.1161/01.CIR.97.16.1532.

3. Fontaine G, Guiraudon G, Frank R. Stimulation studies and epicardial mapping in VT: Study of mechanisms and selection for surgery. Reentrant Arrhythmias, Ed. by H. E. Kulbertus Lancaster, PA: MTP Publishers, 1977:334-50.

4. Campuzano O, Alcalde M, Allegue C, et al. Genetics of arrhythmogenic right ventricular cardiomyopathy. J Med Genet. 2013;50:280-9. doi:10.1136/jmedgenet-2013-101523.

5. Fontaine G, Brestescher C, Fontaliran F, et al. Outcome of arrhythmogenic right ventricular dysplasia. Apropos of 4 case. Arch Mal Coeur Vaiss. 1995;88(7):973-9. ISSN: 0003-9683.

6. Daliento L, Turrini P, Nava A, et al. Arrhythmogenic right ventricular cardiomyopathy in young versus adult patients: similarities and differences. J Am Coll Cardiol. 1995;25(3):655-64. doi:10.1016/0735-1097(94)00433-Q.

7. Rizzo S, Pilichou K, Thiene G, et al. The changing spectrum of arrhythmogenic (right ventricular) cardiomyopathy. Cell Tissue Res. 2012;348(2):319-23. doi:10.1007/s00441-012-1402-z.

8. Blagova OV, Nedostup AV, Morozova NS, et al. Arrhythmogenic right ventricular dysplasia: polymorphism of clinical manifestations. Kardiologiia. 2012;52(4):85-94. (In Russ.)

9. Marcus F, McKenna W, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur Heart J. 2010;31:806-14. doi:10.1161/CIRCULATIONAHA.108.840827.

10. Chin TK, Perloff JK, Williams RG, et al. Isolated noncompaction of left ventricular myocardium: a study of eight cases. Circulation. 1990;82(2):507-13. doi:10.1161/01.CIR.82.2.507.

11. Jenni R, Oechslin E, van der Loo B. Isolated ventricular noncompaction of the myocardium in adults. Heart. 2007;93(1):11-5. doi:10.1136/hrt.2005.082271.

12. Petersen SE, Selvanayagam JB, Wiesmann F, et al. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46(1):101-5. doi:10.1016/j.jacc.2005.03.045.

13. Stollberger C, Finsterer J. Left ventricular hypertrabeculation/ noncompaction. J Am Soc Echocardiogr. 2004;17(1):91-100. doi:10.1016/S0894-7317(03)00514-5.

14. Richards S, Aziz N, Bale S, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24. doi:10.1038/gim.2015.30.

15. Ryzhkova OP, Kardymon OL, Prohorchuk EB, et al. Guidelines for the interpretation of massive parallel sequencing variants (MPS). Medical Genetics. 2017;16(7):4-17. (In Russ.)

16. Blagova OV, Osipova YuV, Nedostup AV, et al. Clinical, laboratory and instrumental criteria for myocarditis, established in comparison with myocardial biopsy examination: a non-invasive diagnostic algorithm. Therapeutic archive. 2017;89(9):30-40. (In Russ.)

17. Groeneweg JA, Bhonsale A, James CA, et al. Clinical Presentation, Long-Term Follow-Up, and Outcomes of 1001 Arrhythmogenic Right Ventricular Dysplasia/ Cardiomyopathy Patients and Family Members. Circ Cardiovasc Genet. 2015;8(3):437-46. doi:10.1161/CIRCGENETICS.114.001003.

18. Mazzanti A, Ng K, Faragli A, Maragna R, et al. Arrhythmogenic Right Ventricular Сardiomyopathy. Clinical Course and Predictors of Arrhythmic Risk. J Am Col Cardiol. 2016;68(23):2540-50. doi:10.1016/j.jacc.2016.09.951.

19. Bauce B, Rampazzo A, Basso C, et al. Clinical phenotype and diagnosis of arrhythmogenic right ventricular cardiomyopathy in pediatric patients carrying desmosomal gene mutations. Heart Rhythm. 2011;8(11):1686-95. doi:10.1016/j.hrthm.2011.06.026.

20. Bhonsale A, Groeneweg JA, James CA, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/ cardiomyopathy-associated mutation carriers. Eur Heart J. 2015;36(14):847-55. doi:10.1093/eurheartj/ehu509.

21. Orgeron GM, James CА, Riele AT, et al. Implantable Cardioverter Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications. J Am Heart Assoc. 2017;6:e006242. doi:10.1161/JAHA.117.006242.

22. Campuzano O, Alcalde M, Iglesias A, et al. Arrhythmogenic right ventricular cardiomyopathy: severe structural alterations are associated with inflammation. J Clin Pathol. 2012;65(12):1077-83. doi:10.1136/jclinpath-2012-201022.

23. Patrianakos AP, Protonotarios N, Nyktari E, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia and troponin release. Myocarditis or the “hot phase” of the disease? Int J Cardiol. 2012;157(2):e26-8. doi:10.1016/j.ijcard.2011.09.017.

24. Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, et al. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2015;12(4):766-73. doi:10.1016/j.hrthm.2015.01.001.

25. Andreoletti L, Leveque N, Boulagnon C, et al. Viral causes of human myocarditis. Arch Cardiovasc Dis. 2009;102(6-7):559-68. doi:10.1016/j.acvd.2009.04.010.

26. Tavora F, Zhang M, Franco M, et al. Distribution of biventricular disease in arrhythmogenic cardiomyopathy: an autopsy study. Hum Pathol. 2012;43(4):592-6. doi:10.1016/j.humpath.2011.06.014.

27. Gilotra NA, Bhonsale A, James CA, et al. Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Circ Heart Fail. 2017;10(9):e003819. doi:10.1161/CIRCHEARTFAILURE.116.003819.

28. Norman MW, McKenna WJ. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: perspectives on disease. Z Kardiol. 1999;88(8):550-4. PMID: 10506390.

29. Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52(25):2175-87. doi:10.1016/j.jacc.2008.09.019.